Cargando…
Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives
The novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and an ongoing severe pandemic. Curative drugs specific for COVID-19 are currently lacking. Chloroquine phosphate and its derivative hydroxychloroquine, which have been used in the treat...
Autores principales: | Zhang, Xiao-lei, Li, Zhuo-ming, Ye, Jian-tao, Lu, Jing, Ye, Lingyu Linda, Zhang, Chun-xiang, Liu, Pei-qing, Duan, Dayue D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7509225/ https://www.ncbi.nlm.nih.gov/pubmed/32968208 http://dx.doi.org/10.1038/s41401-020-00519-x |
Ejemplares similares
-
Pharmacology of Chloroquine and Hydroxychloroquine
por: Browning, David J.
Publicado: (2014) -
TMEM16A Plays an Insignificant Role in Myocardium Remodeling but May Promote Angiogenesis of Heart During Pressure-overload
por: Zhang, Yaofang, et al.
Publicado: (2022) -
Hydroxychloroquine- and chloroquine-related cardiovascular events
Publicado: (2020) -
Systematic Review and Pharmacological Considerations for Chloroquine and Its Analogs in the Treatment for COVID-19
por: Peng, Hongwei, et al.
Publicado: (2020) -
Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456
por: Wan, Jingjing, et al.
Publicado: (2023)